Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union

European Journal of Haematology

Volumn 92, Issue 4, 2014, Pages 289-297

  Moulard, Odile ^a   Mehta, Jyotsna ^a   Fryzek, Jon ^b   Olivares, Robert ^a   Iqbal, Usman ^a   Mesa, Ruben A ^c  

^a Sanofi   (United States)

^b EpidStat Institute   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Epidemiology; Essential thrombocythemia; Europe; Myelofibrosis; Polycythemia vera

Indexed keywords

ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER REGISTRY; CROATIA; DENMARK; EMBASE; EUROPE; EUROPEAN UNION; FINLAND; FRANCE; GERMANY; HEMATOLOGY; HUMAN; MEDICAL DOCUMENTATION; MEDICAL INFORMATION; MYELOFIBROSIS; ONCOLOGY; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; STANDARDIZATION; SWEDEN; SYSTEMATIC REVIEW; THROMBOCYTHEMIA; TREATMENT PLANNING; UNITED KINGDOM; INCIDENCE; META ANALYSIS; PRIMARY MYELOFIBROSIS; STATISTICS AND NUMERICAL DATA; THROMBOCYTHEMIA, ESSENTIAL;

EUROPEAN UNION; HUMANS; INCIDENCE; POLYCYTHEMIA VERA; PREVALENCE; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84896548818     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12256     Document Type: Article

References (34)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2008.
2. National Cancer Institute. Myeloproliferative disorders. http://www.cancer.gov/cancertopics/types/myeloproliferative (Accessed 25 March 2013).
3. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009;115:3842-7.
4. Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005;105:973-7.
5. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-901.
6. Phekoo KJ, Richards MA, Moller H, Schey SA. The incidence and outcome of myeloid malignancies in 2, 112 adult patients in southeast England. Haematologica 2006;91:1400-4.
7. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 2008;83:491-7.
8. Ania BJ, Suman VJ, Sobell JL, et al. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol 1994;47:89-93.
9. Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders: incidence among subtypes according to the Hannover Classification. Pathol Res Pract 1993;189:121-32.
10. Prochazka AV, Markowe HL. The epidemiology of polycythaemia rubra vera in England and Wales 1968-1982. Br J Cancer 1986;53:59.
11. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-61.
12. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009;33:1199-203.
13. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011;118:401-8.
14. International Association of Cancer Registries. www.iacr.com.fr (Accessed 30 November 2012).
15. European Network of Cancer Registries, International Association of Cancer Registries, World Health Organization. www.encr.com.fr (Accessed 30 November 2012).
16. Croatian National Institute of Public Health. Croatian National Cancer Registry. http://www.hzjz.hr/cancer/ (Accessed 30 November 2012).
17. Cancer Statistics. Finnish Cancer Registry. http://www.cancer.fi/syoparekisteri/en/ (Accessed 30 November 2012).
18. Official Statistics of Sweden. Swedish Cancer Registry. http://www.socialstyrelsen.se/register/halsodataregister/cancerregistret/inenglish (Accessed 11 December 2012).
19. Registre des hémopathies malignes de la Gironde. Quelques données issues des 5 premières années de recueil (periode 2002-2006). etudes.isped.u-bordeaux2.fr/REGISTRES-CANCERS-AQUITAINE/ (Accessed 15 December 2012).
20. Orphanet. The portal for rare diseases and orphan drugs. http://www.orpha.net/consor/cgi-bin/index.php (Accessed 1 December 2012).
21. RARECARE. Surveillance of rare cancers in Europe. www.rarecare.eu (Accessed 1 December 2012).
22. Girodon F, Bonicelli G, Schaeffer C, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study. Haematologica 2009;94:865-9.
23. Johansson P, Kutti J, Andreasson B, et al. Trends in the incidence of chronic Philadelphia chromosome negative myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99. J Int Med 2004;256:161-5.
24. Rohrbacher M, Berger U, Hochhaus A, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2008;23:602-4.
25. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. BJC 2011;105:1684-92.
26. Troussard X, Duchenet V, Cornet E, Mouchel D, Malet M, Collignon A. Hematological malignancies: incidence in Basse-Normandie, France, for 1997-2004. Rev Epidémiol Santé Publique 2009;57:e14-24.
27. Berglund S, Zettervall O. Incidence of polycythemia vera in a defined population. Eur J Haematol 1992;48:20-6.
28. Le Guyader-Peyrou S, Gobert E, Menard E, Reiffers J, Monnereau A. Incidence et survie des cas incidents d'hémopathies malignes de la Gironde diagnostiqués sur la période 2002-2006. Communication appears to 6th days Cancéropôle Southwest - Toulouse. October 2010.
29. Mena-Duran AV, Sanchis-Cervera J, Sanchis-Piqueras C. Prevalence of essential thrombocythemia in the JAK2V617F era: a population based study approach in a Spanish community hospital. Haematologica 2009;94(Suppl. 2):587 abs 1510.
30. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2000;65:132-9.
31. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma 2013 [Epub ahead of print].
32. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
33. Najean Y, Rain JD, Billotey C. Epidemiological data in polycythaemia vera: a study of 842 cases. Hematol Cell Ther 1998;40:159.
34. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116:3724-34.